Gossamer Bio (NASDAQ:GOSS) Stock Keeps “Buy” Rating at Chardan Capital

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report issued on Monday, Benzinga reports.

A number of other brokerages also recently weighed in on GOSS. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research report on Tuesday, July 28th. Finally, Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $256.00.

Gossamer Bio Stock Performance

NASDAQ:GOSS traded down $0.64 during midday trading on Monday, reaching $8.97. 100,643 shares of the stock traded hands, compared to its average volume of 240,391. The company has a fifty day moving average of $11.48 and a 200 day moving average of $16.16. Gossamer Bio has a 12 month low of $8.29 and a 12 month high of $309.60. The stock has a market capitalization of $54.79 million, a P/E ratio of -0.16 and a beta of 2.21.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently made changes to their positions in GOSS. Corient Private Wealth LP raised its position in Gossamer Bio by 41.3% during the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after purchasing an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC increased its position in shares of Gossamer Bio by 1,289.4% during the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after purchasing an additional 1,469,175 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Gossamer Bio during the second quarter worth $65,000. Hhlr Advisors LTD. acquired a new position in shares of Gossamer Bio during the second quarter worth $819,000. Finally, ARCH Venture Management LLC acquired a new position in shares of Gossamer Bio during the second quarter worth $1,326,004. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.